Hunan Huateng Pharmaceutical Co. Ltd. news
Hunan Huateng Pharmaceutical Co., Ltd. is excited to announce the availability of three high-quality cosmetic ingredients now in stock and ready for immediate delivery. These trusted actives are ideal for formulations in skin brightening, dandruff control, and sun protection.
Now Available:
Diethylamino Hydroxybenzoyl Hexyl Benzoate (CAS No. 302776-68-7)
A high-efficiency UVA filter with REACH Registration, delivering long-lasting protection against UV-induced skin agi
Versatile compound shows promise in drug synthesis, metal chelation, antioxidant activity, and more
Changsha, China – May 22, 2025– Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical developers worldwide. This compound has gained attention for its multifunctional properties and critical role in drug d
Changsha, China – 18 March 2025 – Hunan Huateng Pharmaceutical Co., Ltd., a global leader in PEG derivatives and CDMO services for APIs and intermediates, is pleased to announce its participation in CPHI Japan 2025. The company will exhibit its comprehensive product lines and cutting-edge capabilities at Booth No. 4X-06, located at Tokyo Big Sight, Tokyo, Japan, from April 9th to 11th, 2025.
Huateng Pharma is dedicated to providing robust support to the biopharmaceutic
Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma’s dedication to meeting the highest regulatory standards and further strengthens its commitment to supp
Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. is proud to provide high-quality monodispersed polyethylene glycols (PEGs) tailored for the evolving needs of antibody-drug conjugates (ADCs). With the ADC market surpassing $10 billion in 2023 and projected to reach $13.13 billion by 2030, our commitment to innovation and quality is stronger than ever.
Among the 15 approved ADCs globally, notable therapies like Trodelvy